ATLASATLAS fair value
₩18,626
Above fair value · 96% premium
Range: ₩12,139–₩23,779Fair valuePrice
Celltrion Pharm (068760.KQ)
Celltrion Pharm stock price today, ATLAS forecast and fair value
Healthcare · Drug Manufacturers - Specialty & Generic · KOSDAQ · South Korea
₩36,550▲ +0.14%
Prices as of Oct 27, 2026 · KRW
Chance of rising in 1 month
50%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Celltrion Pharm in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Celltrion Pharm
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS estimates Celltrion Pharm's fair value at about ₩18,626 per share (reasonable range: ₩12,139 to ₩23,779). At ₩36,550, the stock trades 96% above it.
It is calculated with a blend of a discounted cash-flow model and peer valuation multiples. Confidence in the estimate is medium. It is an estimate, not a promise: if the company's results change, so does its fair value.
ATLAS's model gives Celltrion Pharm a 50% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between ₩34,207 and ₩39,032; in 9 out of 10, between ₩30,430 and ₩43,876. Estimated annual volatility is 36%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- ₩1.6T
- Market cap (USD)
- $1.2B
- P/E ratio
- 67.0
- Dividend yield
- 0.50%
- 52-week high
- ₩78,300
- 52-week low
- ₩35,600
- Revenue (12 months)
- ₩275B
- Gross margin
- 29.4%
- Operating margin
- 11.3%
- Net margin
- 9.5%
- Beta
- 0.90
What this means
These are two different questions: fair value looks at the business (what it is worth given what it earns) and the odds look at the price over the next month. Celltrion Pharm sits above fair value and its odds of rising over a month are close to a coin flip. An expensive stock can keep climbing and a cheap one can keep falling, which is why ATLAS shows the two readings separately.
Over the last 52 weeks 068760.KQ has traded between ₩35,600 and ₩78,300. Today it is 53.3% below that high and 3% above its low.
On the business: net margin is 9.5%; it trades at 67.0 times earnings.
Its beta is 0.90: it moves roughly in line with the market.
About the company
Celltrion Pharm, Inc., a pharmaceutical company, develops and sells biosimilars and over-the-counter drugs in South Korea.
Want to see everything about Celltrion Pharm?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What is Celltrion Pharm (068760.KQ) fair value?
About ₩18,626 per share according to ATLAS (reasonable range: ₩12,139 to ₩23,779). With the stock at ₩36,550, it is 96% above it.
What is the chance 068760.KQ goes up next month?
50%: close to a coin flip. In half of the simulated outcomes, 068760.KQ ends the month between ₩34,207 and ₩39,032.
How big is Celltrion Pharm and what is its P/E ratio?
Celltrion Pharm's market capitalization is ₩1.6T. Its price-to-earnings (P/E) ratio is 67.0: you pay ₩67.0 for each ₩1.00 of yearly earnings.
Does Celltrion Pharm pay a dividend?
Yes. 068760.KQ's current dividend yield is 0.50% at today's price (₩36,550).
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer